AMSBIO: Lentivirus for miRNA Expression and Inhibition
AMSBIO has introduced a range of ready-to-use human and mouse lentivirus products for miRNA and anti-miRNA expression (miRNA inhibition). Lentiviral expression vectors are the most effective vehicles for delivering genetic material to almost any mammalian cell — including non-dividing cells and whole model organisms.
miRNAs are endogenous non-coding RNAs that are highly conserved in mammals and that regulate gene expression post-transcriptionally through innate RNA interference mechanisms. As key players in the fine-tuning of biological networks, miRNAs offer significant diagnostic and prognostic potential as biomarkers not only of fundamental cellular physiology but also of disease etiology and progression.
To study long-term miRNA-induced phenotypes, AMSBIO has developed a range of ready-to-use products for stable expression of the mature miRNA. There are more than 2000 mature miRNA discovered in human and more than 1200 miRNA in mouse so far. miRNA mainly silence or repress gene expression via binding to the complementary sequences of gene coding mRNA. Each miRNA can target multiple genes. It is believed than greater than 60% of mammalian gene expression is regulated by miRNAs, and miRNAs are involved in most biological processes, including a variety of diseases or disorders development.
AMSBIO's range of ready-to-use, anti-miRNA lentivirus (miRNA inhibitors) are produced from the optimally designed anti miRNA lentivectors. The annealed DNA oligonucleotides hairpin duplex encoding the antisense of a specific miRNA sequence are cloned under a constitutive human U6 promoter or under an optional inducible human H1 promoter. AMSBIO’s anti-miRNA lentivector was carefully designed for highest anti-miRNA expression level with precise promoter transcription position, and to favor the antisense strand for RISC complex processing.
Anti-miRNA or miRNA inhibitors are short RNA molecules complementary to the mature miRNA sequence. Anti miRNA specifically binds to endogenous miRNA and it inhibits or down-regulates miRNA activity. Therefore, anti-miRNA is a great tool for the loss of function research of any specific miRNAs. miRNA inhibitors also show potential as therapeutic agents for some biological malfunctions.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance